On February 10, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference (Press release, Aldeyra Therapeutics, FEB 10, 2022, View Source [SID1234607991]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Brady’s conversation with Marc Goodman, Senior Research Analyst at SVB Leerink, will be available on demand beginning at 9:20 a.m. ET Wednesday, February 16, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra website at View Source The event will remain archived on the website for 90 days.

On February 10, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that company management will participate in a fireside chat during Citi’s 2022 Virtual Immuno-Oncology Summit (Press release, Surface Oncology, FEB 10, 2022, View Source [SID1234607990]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation begins at 8 a.m. ET on Wednesday, February 16, 2022. The live audio and subsequent archived webcast of the fireside chat will be accessible from the Events page of the company’s website.

On February 10, 2021 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET (Press release, argenx, FEB 10, 2022, View Source [SID1234607989]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the presentation.

On February 10, 2022 Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET (Press release, Genocea Biosciences, FEB 10, 2022, View Source [SID1234607988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at View Source A replay of the webcast will be archived for 90 days following the presentation.

On February 10, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported its participation in the 11th Annual SVB Leerink Global Healthcare Conference (Press release, Kura Oncology, FEB 10, 2022, View Source [SID1234607986]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.